Roxiant | Startup4eu

HOME
INVESTOR GALLERY
FAQ
Privacy Policy
Log in / Log out
Imprint
eit Health

Select Page

Startup-085

by Startup-Admin | Sep 28, 2021 | Startup

^{Copenhagen, Denmark}
Roxiant is a preclinical stage biotech company developing a new class of medicines to slow, halt, and reverse neurodegenerative diseases. Our drug candidates uniquely activate multifactorial repair mechanisms that counteract age-related cellular damage in human cells.

Manage Cookie Consent

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Functional Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage options Manage services Manage {vendor_count} vendors Read more about these purposes

View preferences

{title} {title} {title}